As if taking advantage of the difficulties when the pharmaceutical company from the United States (US), Moderna Inc. said it was available to supply vaccine supplies to China.
This was said by the Chief Executive Officer (CEO) of Moderna, Stephane Bancel, during an interview regarding the construction of the manufacturing facility for its mRNA products in Japan.
According to Bancel, Moderna is always open and ready to operate at full capacity including supplying its mRNA-based products to China.
He added that Moderna and China had held discussions about the supply of its products some time ago but refused to give further information.
In general, China is still under the control of Covid-19, forcing strict restrictions (lockdown) throughout the country.
In addition, China also has a policy of not approving any overseas Covid-19 vaccine and only relying on domestically produced injections.
However, with winter approaching, there is a possibility that the 'problematic' variant of the virus will increase infections by 20%, which may change the world's position, explained Bancel.
In the meantime, Japan is seen to be starting to relax its vaccination policy by approving the use of booster-shots produced by Moderna and Pfizer Inc against the Omicron variant for its citizens.
As of this writing, Moderna shares are trading up 6.17% at $139.40 with a market capitalization of $54.53 billion.
